Výsledky vyhledávání - "Ćojbašić Irena"

Akademický článek

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib

Autor: Ćojbašić Irena, Mačukanović-Golubović Lana

Publikováno v: Vojnosanitetski Pregled, Vol 68, Iss 11, Pp 911-916 (2011)

Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and

Externí odkaz: https://doaj.org/article/3ab086220e084558b1038460f528c9c3

Zobrazit plný text záznamu

Akademický článek

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy

Autor: Ćojbašić Irena, Mačukanović-Golubović Lana

Publikováno v: Srpski Arhiv za Celokupno Lekarstvo, Vol 138, Iss 5-6, Pp 305-308 (2010)

Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response

Externí odkaz: https://doaj.org/article/acd9698502504cf494bc6242e466259c

Zobrazit plný text záznamu

Akademický článek

Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

Autor: Ćojbašić Irena, Mačukanović-Golubović Lana

Publikováno v: Vojnosanitetski Pregled, Vol 67, Iss 10, Pp 802-806 (2010)

Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). It

Externí odkaz: https://doaj.org/article/b9e3e1318e344cc987855c51fb10ad0d

Zobrazit plný text záznamu